Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by tim_kon Mar 01, 2012 12:20am
521 Views
Post# 19609054

I'm back in

I'm back in

I violated my rule of never buying/selling in the first 30 minutes of open ... and I paid for it a bit getting back in at 0..85 :-( 

But, I'm still relatively happy. Last time I was in when the 21 DMA crossed the 50 DMA ... and made a nice little profit before moving on ... now that the MACD is close to being positive and the 50 DMA is about to cross the 200 DMA ... I'm back in for a little bit of a run. 

Maybe nothing much happens for a while, but the momentum is set up for a trade. I don't use technicals much in pennies, but indicators and moving averages still tell a story. 

I'm not disappointed by the news release. It's par for the course. I'm just in it for a short trade, hopefully back out by March 15th. I'll get back in closer to spudding of flami.

and if its a bad trade, I'll just average down, hard to see this thing stay below 0.10 for too much longer 

Good luck all!

Bullboard Posts